Abstract: The present invention relates to a process for preparing amino-functional polyurethane prepolymers by a) preparing an NCO-functional polyurethane prepolymer by reacting an excess of one or more di- and/or polyisocyanates with at least one isocyanate-reactive compound having a functionality of at least 1.5, b) reacting the free NCO groups of the resulting polyurethane prepolymer with at least one compound containing one or more silanol groups to obtain the corresponding silylurethanes, and then c) converting the silylurethanes to amino-functional polyurethane prepolymers by hydrolysis and/or alcoholysis with decarboxylation. The present invention also relates coatings, adhesives, sealants, casting compounds or moldings obtained from these amino-functional polyurethene prepolymers.

Abstract: Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment are provided herein. The compounds described herein are useful as anti-neoplastic agents, i.e., to inhibit tumor cell growth in vitro or in vivo, in mammalian hosts, such as humans or animals, e.g., domestic animals, and are effective against solid tumors, hematologic malignancies and multi-drug resistant cancers/tumors. The present compounds can be used alone or they can be used in combination with one or more anti-cancer or anti-tumor agents.

Abstract: The present invention describes 1-aminoadamantane derivatives and 3-aminoadamantane-1-carboxylic derivatives in which the 5- or 7-position of the basic adamantane structure can be optionally substituted, methods for the production of the compounds based on the present invention, and methods for the coupling of the monomeric 3-aminoadamantane-1-carboxylic derivatives thus obtained to oligomers. The compounds based on the present invention are suitable for the utilisation as antiviral active ingredients, artificial ion channels, as well as for the therapy, diagnostics and prophylaxis of diseases in which a dysfunction of the GABA system occurs.

Abstract: A crystalline rivastigmine hydrogentartrate of Form II and an amorphous rivastigmine hydrogentartrate of Form III.

Abstract: Compounds of the formula I: wherein R1, R2, X and N are as defined in the specification; E is N, CH; A? and A? are terminal groups as defined in the specification. The compounds have utility as HIV-1 protease inhibitors.

Abstract: A cascade carrier linked prodrug is described which comprises a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier.

Abstract: The synthesis of 1-(acyloxy)-alkyl carbamates of GABA analogs from 1-haloalkyl carbamates of GABA analogs are described. Also described are new 1-haloalkyl carbamates of GABA analogs.

Abstract: The present invention relates to novel substituted benzyloxy-phenylmethylamide derivatives, processes for their preparation, and their use in medicaments, especially for the prophylaxis and treatment of diseases associated with Cold Menthol Receptor 1 (CMR-1) activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

Abstract: The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions.

Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

Abstract: Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of making acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of using acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, and pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs 3-aminopropylphosphinic acid and analogs thereof for treating diseases or disorders such as mild cognitive impairment, cognitive impairment associated with Alzheimer's disease Alzheimer's disease, depression, anxiety, and epilepsy are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, which are suitable for oral administration and sustained release oral dosage forms are also disclosed.

Abstract: Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid, pharmaceutical compositions thereof, methods of making prodrugs of trans-4-(aminomethyl) -cyclohexane-carboxylic acid, and methods of using prodrugs of trans-4-(aminomethyl) -cyclohexanecarboxylic acid and pharmaceutical compositions thereof to treat or prevent various diseases or disorders are disclosed. Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl) -cyclohexanecarboxylic acid and pharmaceutical compositions thereof suitable for oral and topical administration and for administration using sustained release dosage forms are also disclosed.

Abstract: High-functionality polyisocyanates are prepared by a process which comprises (i) preparation of an addition product (A) which contains one group which is reactive toward isocyanate and at least two isocyanate groups by reacting (a) a diisocyanate or polyisocyanate I with (b1) compounds having at least three groups which are reactive toward isocyanate or (b2) compounds containing two groups which are reactive toward isocyanate or mixtures of (b1) and (b2), where at least one of the components (a) or (b) has functional groups having differing reactivities toward the functional groups of the other component and the reaction ratio is selected so that the addition product (A) contains an average of one group which is reactive toward isocyanate, (ii) if desired, intermolecular addition reaction of the addition product (A) to form a polyaddition product (P) containing an average of one group which is reactive toward isocyanate and an average of more than two isocyanate groups, and (iii) reaction of the addition

Abstract: The present invention concerns a process for producing low-viscosity polyisocyanates or secondary products thereof, which carry activated, radiation-curable double bonds and can optionally also cure thermally, and low-viscosity polyisocyanate mixtures or secondary products thereof and their use in coating compounds.

Abstract: Curable trans-1,2-cyclohexane bis(urea-urethane) compounds of the formulae wherein R1 and R?1 each, independently of the other, are alkylene, arylene, arylalkylene, or alkylarylene groups, R2 and R?2 each, independently of the other, are alkyl, aryl, arylalkyl, or alkylaryl groups, R3 and R?3 each, independently of the other, are hydrogen atoms or alkyl groups, R4 and R?4 each, independently of the other, are hydrogen atoms, fluorine atoms, alkyl groups, or phenyl groups, n is an integer of 0, 1, 2, 3, or 4, and R5 is an alkyl, aryl, arylalkyl, or alkylaryl group, or a substituent other than an alkyl, aryl, arylalkyl, or alkylaryl group, provided that at least one of R1, R?1, R2, R?2, R3, R?3, R4, R?4, or one or more of R5 is an alkyl, alkylene, arylalkyl, arylalkylene, alkylaryl, or alkylarylene group containing an ethylenic unsaturation rendering the compound curable upon exposure to heat and/or actinic radiation.

Abstract: Disclosed are trans-1,2-cyclohexane bis(urea-urethane) compounds of the formulae wherein R1 and R?1 each, independently of the other, is an alkylene group, an arylene group, an arylalkylene group, or an alkylarylene group, R2 and R?2 each, independently of the other, is an alkyl group, an aryl group, an arylalkyl group, or an alkylaryl group, R3 and R?3 each, independently of the other, is a hydrogen atom or an alkyl group, R4 and R?4 each, independently of the other, is a hydrogen atom, a fluorine atom, an alkyl group, or a phenyl group, n is an integer of 0, 1, 2, 3, or 4, and R5 is an alkyl group, an aryl group, an arylalkyl group, an alkylaryl group, or a substituent other than an alkyl, aryl, arylalkyl, or alkylaryl group.

Abstract: The present invention provides a process of starting from N-alkoxycarbonyl-ethylamine compounds having a leaving group at the ?-position to prepare oxazolidinone derivatives of ?-hydroxyethylamine compounds having an inverted steric configuration at the ?-position carbon, which comprises introducing a step of treating in contact with water with heating under acidic to neutral conditions into the process. Also, the present invention provides a process of starting from N-alkoxycarbonyl-ethylamine compounds having a leaving group at the ?-position to prepare ?-hydroxyethylamine compounds having an inverted steric configuration at the ?-position carbon, which comprises subjecting the oxazolidinone derivatives prepared as described above to a step of treating in contact with water under basic conditions.

Abstract: The present invention provides a process for producing an optically active 2-allylcarboxylic acid derivative, which is useful as a pharmaceutical intermediate, from readily available and inexpensive starting materials by the process which can be practiced on a commercial scale in a simple and easy manner, and certain 2-allylcarboxamide derivatives, which are novel and important intermediates in that process. An N-allylcarboxamide derivative undergoes rearrangement reaction diastereoselectively in the presence of a base to give a 2-allylcarboxamide derivative, the resulting derivative is subjected to a carbamation reaction and solvolysis to give an optically active 2-allylcarboxylic acid ester, and then the ester obtained is stereoselectively hydrolyzed using an enzyme to produce 2-allylcarboxylic acid having a high optical purity. In addition, the present invention provides a 2-allylcarboxamide derivative compound which is a novel intermediate in the process of the present invention.

Abstract: The present invention relates to substantially pure piperidine derivative compounds of the formulae: wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; R3 is —COOH or —COOR4; R4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.

Abstract: The synthesis of 1-(acyloxy)-alkyl carbamates of GABA analogs from 1-haloalkyl carbamates of GABA analogs are described. Also described are new 1-haloalkyl carbamates of GABA analogs.

Abstract: A process for a preparation of Compound (V), a pharmaceutically acceptable salt or a solvate thereof, said process comprising the steps represented by the following formula: wherein R1 and R2 are each independently C1–C8 alkyl.

Abstract: The present invention relates to new hydrophilicized blocked polyisocyanates, a process for preparing them and their use.

Abstract: Cyclic ?-(acylamino)acrylate derivatives were hydrogenated using Ru-chiral phosphine ligand catalysts and thereafter converted to the corresponding cyclic ?-aminoacids in high yield and enantioselectivity according to the reaction scheme:

Abstract: The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

Abstract: Fatty acid amide hydrolase inhibitors of the Formula: are provided wherein X is NH, CH2, O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or unsubstituted terphenylyl; substituted or unsubstituted cycloalkyl, heteroaryl, or alkyl; and R1 and R2 are independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted phenyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; with the proviso that if Z is O, one of R1 and R2 is absent, and that if Z is N, optionally R1 and R2 may optionally be taken together to form a substituted or unsubstituted N-heterocycle or substituted or unsubstituted heteroaryl with the N atom to which they

Abstract: 5-[(4-chlorophenyl)methyl]-2,2-dimethylcyclopentanone is produced by reacting 1-[(4-chlorophenyl)methyl]-3-methyl-2-oxocyclopentanecarboxylic acid methyl ester or 1-[(4-chlorophenyl)methyl]-3-methyl-2-oxocyclopentanecarboxylic acid ethyl ester with sodium hydride and methyl halide, then hydrolyzing the obtained 1-[(4-chlorophenyl)methyl]-3,3-dimethyl-2-oxocyclopentanecarboxylic acid methyl ester or 1-[(4-chlorophenyl)methyl]-3,3-dimethyl-2-oxocyclopentanecarboxylic acid ethyl ester. The process provides 5-[(4-chlorophenyl)methyl]-2,2-dimethylcyclopentanone, an important intermediate of an agricultural or horticultural fungicide, e.g., Metconazole.

Abstract: Pleuromutilin compounds of the formula: are of use in anti-bacterial therapy.

Abstract: The invention relates to urethane prepolymers, obtainable by reaction of: (A) 15 to 85 wt.-% of one or more ?,?-terminated poly(meth)acrylate diols, (B) 0 to 30 wt.-% of one or more radically curable, polyhydroxy-functional compounds, (C) 14 to 60 wt.-% of one or more polyisocyanates, (D) 1 to 40 wt.-% of a monofunctional compound, reactive vis-à-vis isocyanate groups, which also contains one or more radically curable grouping, as well as their use.

Abstract: At least one isocyanate-reactive monomer is reacted with an excess of molten monomeric diisocynate to produce at least one reaction product and a maximum of 0.5 wt % of free isocyanate groups. The reaction product is then mixed with at least 20 wt. %, based on the total weight of reaction product, of at least one isocyanate-terminated prepolymer which is essentially free of diisocyanate monomers and has a viscosity at 20° C. of at least 1.500 mPa·s, the isocyanate-terminated prepolymer having a content of free NCO groups of up to 25 wt % and containing a maximum of 0.1 wt. % of diisocyanate monomer(s) based on the weight of the isocyanate-terminated prepolymer. A polyurethane composition containing less than 0.1 wt. % of monomeric diisocyanate, based on the total weight of the resulting polyurethane composition, is produced.

Abstract: Polyurethane compositions are produced in a two-stage method. In a first step, a diol component with a molecular weight of less than 2000 is reacted with a monomeric diisocyanate with a molecular weight of less than 500 and the unreacted monomeric diisocyanate is removed from this reaction product. In a second step, the resulting high-molecular diisocyanate is reacted with a polyol to produce a reactive prepolymer with isocyanate and groups. The addition of polyisocyanates which are capable of migration and which have a substantially lower vapor pressure than diphenylmethanediisocyanate, improves the addition behavior of the invention polyurethane compositions. Reactive polyurethane compositions of this type are suitable for using as binding agents for reactive one or two component adhesives/sealants, which may optionally contain solvents. These compositions are also suitable for producing reactive hot melt adhesives when suitable polyols are selected.

Abstract: The present invention relates to a composition and use of polymeric urethane esters quats as an active ingredient for skin and hair contacting personal care compositions and products related thereto. These compositions are generally produced by the reaction of a trialkanolamine with a hydroxy fatty acid to produce a trialkanolamine fatty acid ester, which is then polymerized with a diisocyanate and in preferred embodiments, further reacted with a quaternizing agent to produce preferred quaternized compositions according to the present invention.

Abstract: The present invention is directed to compositions comprising polymeric tertiary amines of urethane esters and salts thereof. The compositions are generally derived from linear or branched chain compounds of synthetic or natural origin, preferably from trialkalnolamines that have been esterified with organic acids including long chain fatty acids and reacted with diisocyanate compounds to form urethane adducts. These adducts are in turn polymerized with organic acids to form polymeric urethane ester tertiary amine salts. The compositions of the present invention may be incorporated into personal care formulations such as cosmetics, toiletries and shampoos and into detergents to improve or modify at least two of the characteristics of such formulations.

Abstract: Compounds of the formula (I) in which: R1 is (CH2)nY; n is 1 or 2; Y is NHSO2R2 or X1—W—X2—R3; X1 is O or NH; W is C?O, C?S, C?NH, or SO2; X2 is O or NH, provided that X1 and X2 are not both O; R2 is C1-10 alkyl; C2-10 alkenyl; C2-10 alkynyl; aryl; aryl-C1-10 alkyl; aryl-C2-10 alkenyl; aryl-C2-10alkynyl; C3-8 cycloalkyl or C3-8-cycloalkyl-C1-10 alkyl; and R3 is hydrogen, C1-10alkyl; C2-10 alkenyl; C2-10 alkynyl; aryl; aryl-C1-10 alkyl; aryl-C2-10 alkenyl; aryl-C2-10 alkynyl; C3-8 cycloalkyl; or C3-8-cycloalkyl-C1-10 alkyl; or a salt or ester thereof, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.

Abstract: Blocked polyisocyanates and one-component stoving systems containing these blocked polyisocyanates, and the preparation thereof and their use for the preparation of lacquers, paints, adhesives and elastomers. The blocked polyisocyanates are derived from polyisocyanates reacted with secondary amines and cationic, anionic and/or nonionic hydrophilizing agents such that they are incorporated into the polyisocyanate at a ratio of from 20:1 to 1:1, wherein the blocking agents correspond to the formula R1–R4 can be identical or different and independently of one another denote hydrogen, C1–C6-alkyl or C3–C6-cycloalkyl, R5 denotes C1–C10-alkyl, C3–C10-cycloalkyl, and B represents ?wherein R6–R8 can be identical or different and independently of one another denote C1–C6-alkyl and/or C1–C6-cycloalkyl, R9 denotes hydrogen or C3–C6-alkyl or C3–C6-cycloalkyl.

Abstract: A process for the production of polyurethane di(meth)acrylates in which a diisocyanate component, a diol component and hydroxy-C2–C4-alkyl (meth)acrylate in the molar ratio x:(x?1):2 are reacted without solvent and without subsequent purification operations, wherein x means any desired value from 2 to 5, wherein 50 to 80 mol % of the diisocyanate component is formed by 1,6-hexane diisocyanate, and 20 to 50 mol % by one or two diisocyanates, each forming at least 10 mol % of the diisocyanate component and being selected from the group consisting of toluylene diisocyanate, diphenylmethane diisocyanate, dicyclohexylmethane diisocyanate, isophorone diisocyanate, trimethylhexane diisocyanate, cyclohexane diisocyanate, cyclohexanedimethylene diisocyanate and tetramethylenexylylene diisocyanate, wherein the mol % of the respective diisocyanates add up to 100 mol %, wherein the diol component comprises no more than four different diols, and 20 to 100 mol % of the diol component is formed by at least one linear alipha

Abstract: Phase change ink carrier compositions comprising an admixture of (1) at least one urethane resin; and/or (2) at least one mixed urethane/urea resin; and/or (3) at least one mono-amide; and/or (4) at least one polyethylene wax are provided. In addition, a phase change colored ink of such carrier compositions comprising a phase change ink compatible colorant are also provided. Embodiments of the present invention also include methods for producing a layer of the above phase change colored ink on the surface of a substrate by either direct or indirect printing. Such methods also encompassing using a polyethylene wax as an overcoat layer above such a phase change ink layer on a printed substrate.

Abstract: The invention concerns the use of a solid basic catalyst comprising a hydrotalcite structure wherein part at least of the compensating anions are fluoride anions F? for producing Knoevenagel of Michael condensation reactions. The invention also concerns novel solid basic catalysts comprising a hydrotalcite structure characterized by a Mg/Al molar ratio ranging between 2.5 and 3.8 wherein at least part of the compensating anions are fluoride anions F?, and methods for preparing said novel catalysts.

Abstract: A polyol composition having a number average molecular weight of from about 1,000 to about 3,000 Daltons is made up of (1) at least 60% by weight of a low monol polyoxypropylene polyol having a number average molecular weight of from about 2,000 to 12,000 Da and a degree of unsaturation less than or equal to 0.02 meq/g and (2) no more than 40% by weight of a polyol having a number average molecular weight of from about 400 to about 1,000 Da and a polydispersity index greater than 1.1. This polyol composition is reacted with a diisocyanate, a polyisocyanate, an isocyanate-terminated prepolymer or an isocyanate-terminated quasi-prepolymer to produce polyurethane elastomers having good physical and mechanical properties. Any of the known processes for producing polyurethane elastomers, including one-shot processes, may be used to produce elastomers in accordance with the present invention.

Abstract: A process for preparing polyisocyanate prepolymers containing allophanate structural units that includes reacting a) one or more polyisocyanates with b) one or more polyetherpolyols containing less than or equal to 0.02 milliequivalent of unsaturated end groups per gram of polyol and having a polydispersity of from 1.0 to 1.5 and/or an OH functionality of greater than or equal to 1.9 ?to provide an NCO-functional polyurethane prepolymer containing urethane groups that are partly or fully allophanatized by further reaction with c) polyisocyanates, which may be different from those from a), and d) catalysts and optionally adding e) acidic additives before, during and/or after the allophanatization. The polyisocyanate prepolymers can be used to produce coatings, adhesive bonds and/or seals. The coatings include one or more of the polyisocyanate prepolymers, and at least one diol or polyol and/or at least one linear and/or cyclic, aliphatic, araliphatic and/or aromatic diamine or polyamine.

Abstract: A blocked polyisocyanate adduct including 5 to 95% by weight of at least one isocyanate component having at least one NCO group, the isocyanate component selected from the group consisting of aliphatic, cycloaliphatic and aromatic isocyanates, wherein the isocyanate has an average molecular weight of up to 1000 g/mol and an average NCO functionality of 2–4; 5 to 70% by weight of at least one hydrophilicizing component containing at least one group which is reactive toward the at least one NCO group; at least one blocking agent for blocking from 95 to 100% of the NCO groups which do not react with the hydrophilicizing component; and up to 15% by weight of at least one neutralizing agent.

Abstract: The invention concerns a novel catalyst for forming urethanes. Said catalyst is characterized by the general formula: MY3?q[Z]q, wherein: Z is the radical corresponding to the anion of a super acid whereof the Hamett constant is at least equal to 13 and advantageously more than 13, M representing a trivalent metal, preferably known for forming Lewis acids; Y is an anion or a monovalent anionic function; and q is an integer selected advantageously between 1 and 3, inclusively. The invention is applicable to paint.

Abstract: In one embodiment, the present application relates to a process of making a compound of formula I: and to certain intermediate compounds that are made within the process of making the compound of formula I.

Abstract: Provided is a compound having one or more structures of the formula: wherein X is a primary carbamate group, Y is a hydroxy or halide group, n is an integer of 2 or more, n? is an integer of 1 or more, and R0, R1, R2, R3, R4 and R5 may be H or a group selected from alkyl groups, aliphatic groups, cycloaliphatic groups, aromatic groups and mixtures thereof, with the provisos that at least one R1 or R2 group is selected from the group consisting of aliphatic groups, cycloaliphatic groups, and aromatic groups, and in substantially all structures primary carbamate group X is attached to a carbon atom having a lower degree of substitution than a carbon atom to which functional group Y is attached. The invention provides a method of making the claimed compound.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, X, W, m and n are as defined hereinabove. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

Abstract: Valency platform molecules comprising high molecular weight polyethylene oxide groups are provided, as well as conjugates thereof with biologically active molecules, and methods for their preparation. The high molecular weight polyethylene oxide group has, for example, a molecular weight of greater than 22,000 Daltons, for example at least 40,000 Daltons. In one embodiment, a composition comprising the valency platform molecules is provided, wherein the molecules have a polydispersity less than about 1.2. Conjugates of the valency platform molecule and a biologically active molecule, such as a saccharide, poly(saccharide), amino acid, poly(amino acid), nucleic acid or lipid also are provided. Also provided are pharmaceutically acceptable compositions comprising the conjugates disclosed herein and a pharmaceutically acceptable carrier, as well as methods of making and using the conjugates and compositions.

Abstract: A prepolymer is prepared by reacting a mixture containing (a) at least one multifunctional compound, (b) at least one diisocyanate, and (c) at least one diol. The diol has a weight average molecular weight of at most 6000. The prepolymer, when reacted with an excess of water, forms a hydrogel polymer. The mixture of the prepolymer and water may be reaction molded, and used to form a contact lens.

Abstract: Pleuromutilin compounds of the formula: are of use in anti-bacterial therapy.

Abstract: Catalysts contain, as structural units, at least one tertiary amino group and at least one group which, after its decomposition, is capable of complexing or protonating the tertiary amino group.

Abstract: Using at least one compound selected from the group consisting of a zirconyl compound and a zirconium alcoholate as an allophanation catalyst, an allophanate group-containing polyisocyanate composition is produced from a starting material of at least one isocyanate compound selected from the group consisting of an aliphatic diisocyanate, an alicyclic diisocyanate and an isocyanate pre-polymer obtained therefrom, and another starting material of a hydroxyl group-containing compound.

Abstract: This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.